Results 61 to 70 of about 1,083 (145)

Giant prolactinoma: the sound of silence

Endocrinology Studies, 2014
Prolactinomas typically present with oligoamenorrhea or galactorrhea in woman and headaches, visual changes or impotence in men with auditory symptoms being a rare presentation. We describe a case of a man who presented with bilateral hearing loss and was found to have a giant prolactinoma.
Shira R. Saul, Maya P. Raghuwanshi
openaire   +1 more source

Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas

Endocrine Oncology
Prolactinomas are the most common hypersecretory pituitary adenoma. The traditional first-line therapy is dopamine agonists (DAs), which are highly effective and tolerated in the majority of cases.
Edward Mignone, Alistair K Jukes, Rowan Valentine, Richard Allison, Sunita M C De Sousa   +4 more
doaj   +1 more source

Restoration of fertility in a woman with giant prolactinoma in response to cabergoline treatment

Endocrinology, Diabetes & Metabolism Case Reports, 2019
A 32-year-old woman presented with primary amenorrhoea, prolactin (PRL) level of 154 150 mIU/L and was diagnosed with a giant pituitary adenoma measuring maximum 6.2 cm.
L I Astaf’eva, Y G Sidneva, B A Kadashev, P L Kalinin, G A Melnichenko, S A Agadzhanian   +5 more
doaj   +1 more source

Clinical Outcome of Invasive Pituitary Prolactinomas Treated with Cabergoline

مجله كليه طب الكندي, 2020
Background: Treatment of invasive prolactinoma, which has several characteristics including invasive growth into cavernous sinuses and formation of giant adenomas compressing adjacent neural structures, resulting in neurological dysfunction, has been ...
Bassam M Flamerz Arkawazi
doaj   +1 more source

Long-term primary pharmacotherapy of giant prolactinomas: A comparison of different cabergoline dosages

Journal of Clinical & Translational Endocrinology
Objectives: Dopamine agonists serve as first-line therapies for most giant prolactinomas. The objective of this study was to assess the differential impact of dopamine agonist dosing strategies on biochemical (prolactin normalisation) and radiological ...
Hána Václav Jr., Vaněčková Manuela, Kršek Michal, Krausová Adéla, Ježková Jana, Kosák Mikuláš, Diblík Pavel, Netuka David, Masopust Václav, Májovský Martin, Liščák Roman, Hána Václav   +11 more
doaj   +1 more source

Clinical and Hormonal Criteria of the Effectiveness of Suppressive Cabergoline Therapy in Patients with Organic Hyperprolactinemia

Mìžnarodnij Endokrinologìčnij Žurnal, 2015
Background. In modern international guidelines, there are not distinguished criteria for the evaluation of clinical symptoms, including somatic, neurological status, although almost all neuroendocrinologists acknowledge the presence exactly of ...
O.O. Khyzhniak, T.H. Hohitidze, M.R. Mykytiuk   +2 more
doaj   +1 more source

Rapid Visual Improvement After Cabergoline Therapy in a Macroprolactinoma Case

Endocrinology Research and Practice, 2018
Introduction: Medical therapy with dopamin agonists (DAs) is the first treatment of choice for prolactinomas. no matter how large or how severe the neurologic sequelae and cabergoline (CAB) is the best initial choice (1).
Elif Güneş, Şirin Zelal Şahin Tırnova, Erdinç Ertürk   +2 more
doaj   +1 more source

The Heterogeneity of Serum hPRL in a Patient with a Giant Prolactinoma

Folia Endocrinologica Japonica, 1984
The heterogeneity of hPRL in the serum of a patient with a giant prolactinoma (hPRL 27 micrograms/ml) was studied employing gel chromatography, RIA and lymphoma cell bioassay. After gel filtration of serum sample on Sephadex G-100 (superfine) column, a few hPRL peaks were detected by RIA.
TANAKA, Toshiaki, AIBA, Tadashi, SHISHIBA, Yoshimasa   +2 more
openaire   +3 more sources

Cabergoline monotherapy in GH- and PRL-cosecreting pituitary adenomas

Endocrine Oncology
Functional pituitary tumours, also called pituitary neuroendocrine tumours (PitNETs), typically produce a single hormone, based on the cell lineage from which they arise in the anterior pituitary.
James M McNeil, Nicholas C Candy, Alistair K Jukes, Sunita M C De Sousa   +3 more
doaj   +1 more source

Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report

Journal of Medical Case Reports, 2019
Background Prolactinomas are tumors of the pituitary gland that usually respond very well to treatment with cabergoline. Resistance to cabergoline is very rare, but when it occurs, it is a difficult problem to resolve if the tumor is inoperable.
Luiz Augusto Casulari, Lucas Faria de Castro, Iruena Moraes Kessler, José Luiz Mendonça, Maria de Fátima Magalhães Gonzaga   +4 more
doaj   +1 more source